Nothing said here yet.
to join the conversation.
| Massacesi CristianEVP,Chief Med Offr,Head of Dev | Sell | 6,249 | $403.5K | Wed, Sep 9 |
| Holzer Phil MSVP and Controller | Sell | 500 | $33.8K | Tue, Aug 25 |
| Thomas H Tuberville | Sell | $8.0K | Tue, Apr 15 | Wed, Aug 5 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Mike Kelly | Sell | $32.5K | Thu, May 7 | Wed, Jun 10 |
Bristol-Myers Squibb reported Q3 2026 revenue of US$13.07b and net income of US$2.16b, beating analyst expectations and prompting higher full-year sales guidance, while EPS guidance was updated after an 11.57% earnings surprise.
Bristol-Myers Squibb (NYSE:BMY) and BioNTech reported positive Phase 2 data for pumitamig in metastatic non-small cell lung cancer.
BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.
Bristol Myers Squibb (NYSE:BMY) raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments…
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
Bristol Myers Squibb (NYSE:BMY) reported third-quarter 2026 earnings and revenue above analysts’ expectations on Thursday, raising its full-year sales forecast while updating its adjusted earnings guidance.
Bristol Myers Squibb stock rose Thursday despite a "mixed bag" performance that included a miss from its biggest cancer drug.
Bristol Myers Squibb stock dipped early Thursday on lighter-than-expected Opdivo sales and an earnings guidance haircut.
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.